Live Breaking News & Updates on Elanaj Fertig

Stay updated with breaking news from Elanaj fertig. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Personalized Vaccine for Liver Cancer Shows Promise in Clinical Trial

Adding a personalized anti-tumor vaccine to standard immunotherapy is safe and about twice as likely to shrink cancer as standard immunotherapy alone for patien ....

Cooper City , United States , University Of Central Florida , New Zealand , New York , Elanaj Fertig , Bristol Myers Squibb Incyte , Johns Hopkins , Elizabeth Jaffee , Lucianet Kagohara , Danielh Shu , Bristol Meyers Squibb , Mark Yarchoan , Johns Hopkins University , Personalis Inc , Convergence Institute , Our Cancer Convergence Institute , Wistar Institute , Johns Hopkins University School Of Medicine , Home Group , University Of Auckland , Immunotherapy Center , Johns Hopkins Kimmel Cancer Center , Icahn School Of Medicine At Mount Sinai , Kimmel Cancer Center , University Of Central Florida College Medicine ,

Personalized Vaccine for Liver Cancer Shows Promise in Clinical Trial

Adding a personalized anti-tumor vaccine to standard immunotherapy is safe and about twice as likely to shrink cancer as standard immunotherapy alone for patien ....

United States , Cooper City , New Zealand , New York , University Of Central Florida , Elanaj Fertig , Bristol Myers Squibb Incyte , Johns Hopkins , Lucianet Kagohara , Elizabeth Jaffee , Bristol Meyers Squibb , Mark Yarchoan , Danielh Shu , Johns Hopkins Kimmel Cancer Center , Home Group , Immunotherapy Center , University Of Auckland , Wistar Institute , Johns Hopkins University School Of Medicine , Personalis Inc , Johns Hopkins University , Our Cancer Convergence Institute , Convergence Institute , American Association For Cancer Research , Parker Institute , Tisch Cancer Institute ,

Mechanism for how pancreatic cancer evades immunotherapy elucidated

E-Mail
WASHINGTON - Pancreatic cancer, one of the most lethal of all cancers, is capable of evading attacks by immune cells by changing its microenvironment so that the immune cells suppress, rather than support, an attack on the tumor. The scientists also found that that some of the mediators of this suppressive response, including a protein called STAT1, represent potential therapeutic targets that could be used to reverse this evasion and point to possible treatment opportunities.
The finding appears January 28, 2021, in
Cancer Immunology Research.
This is the first demonstration that an immune attack induces pancreatic cancer-derived immune suppression, offering a new approach to immunotherapy for this deadly cancer, noted Louis M. Weiner, M.D., director of Georgetown Lombardi and the Principal Investigator of this study. ....

Lombardi Cancer Center , District Of Columbia , United States , Johns Hopkins University , Department Of Energy , Saudi Arabia , Oak Ridge , Georgetown University , Saudi Arabian , Yue Shen , Louism Weiner , Zoex Malchiodi , Annie Zuo , Jeremyc Smith , Connorj Cooper , Quentinr Johnson , Shangzi Wang , Allisona Fitzgerald , Reham Ajina , Sandraa Jablonski , Maha Moussa , Elanaj Fertig , Marta Catalfamo , Cancer Immunology Research , Leidos Biomedical Research Inc , Hemerson Foundation ,